Hypera Sa Stock Fundamentals
| HYPE3 Stock | BRL 20.05 0.45 2.20% |
Hypera SA fundamentals help investors to digest information that contributes to Hypera SA's financial success or failures. It also enables traders to predict the movement of Hypera Stock. The fundamental analysis module provides a way to measure Hypera SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hypera SA stock.
Hypera |
Hypera SA Company Profit Margin Analysis
Hypera SA's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Hypera SA Profit Margin | 0.23 % |
Most of Hypera SA's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hypera SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Hypera SA has a Profit Margin of 0.2299%. This is 102.05% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The profit margin for all Brazil stocks is 118.1% lower than that of the firm.
Hypera SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hypera SA's current stock value. Our valuation model uses many indicators to compare Hypera SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hypera SA competition to find correlations between indicators driving Hypera SA's intrinsic value. More Info.Hypera SA is rated # 4 in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers reporting about 0.42 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Hypera SA is roughly 2.37 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hypera SA's earnings, one of the primary drivers of an investment's value.Hypera Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hypera SA's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hypera SA could also be used in its relative valuation, which is a method of valuing Hypera SA by comparing valuation metrics of similar companies.Hypera SA is currently under evaluation in profit margin category among its peers.
Hypera Fundamentals
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0686 | |||
| Profit Margin | 0.23 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 33.47 B | |||
| Shares Outstanding | 631.94 M | |||
| Shares Owned By Insiders | 36.24 % | |||
| Shares Owned By Institutions | 40.62 % | |||
| Price To Earning | 13.10 X | |||
| Price To Book | 2.55 X | |||
| Price To Sales | 3.79 X | |||
| Revenue | 5.94 B | |||
| Gross Profit | 3.8 B | |||
| EBITDA | 2.16 B | |||
| Net Income | 1.33 B | |||
| Cash And Equivalents | 2.24 B | |||
| Cash Per Share | 3.24 X | |||
| Total Debt | 6.85 B | |||
| Debt To Equity | 0.70 % | |||
| Current Ratio | 1.93 X | |||
| Book Value Per Share | 16.57 X | |||
| Cash Flow From Operations | 1.4 B | |||
| Earnings Per Share | 2.57 X | |||
| Price To Earnings To Growth | 1.37 X | |||
| Target Price | 53.34 | |||
| Number Of Employees | 9 K | |||
| Beta | 0.24 | |||
| Market Capitalization | 28.34 B | |||
| Total Asset | 19.82 B | |||
| Retained Earnings | 2.62 B | |||
| Working Capital | 5.04 B | |||
| Current Asset | 6.68 B | |||
| Current Liabilities | 1.63 B | |||
| Z Score | 2.4 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 3.41 % | |||
| Net Asset | 19.82 B | |||
| Last Dividend Paid | 1.23 |
About Hypera SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hypera SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hypera SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hypera SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.It offers branded prescription products under the Mantecorp Farmasa, Episol, Predsim, Alivium, Lisador, Rinosoro, Celestamine, Maxsulid, Diprospan, Mioflex-A, and Addera D3 brands dermo-cosmetics products under the Mantecorp Skincare brands and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. Hypera S.A. was founded in 2001 and is headquartered in So Paulo, Brazil. HYPERA ON operates under Drug ManufacturersSpecialty Generic classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 8918 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hypera Stock Analysis
When running Hypera SA's price analysis, check to measure Hypera SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hypera SA is operating at the current time. Most of Hypera SA's value examination focuses on studying past and present price action to predict the probability of Hypera SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hypera SA's price. Additionally, you may evaluate how the addition of Hypera SA to your portfolios can decrease your overall portfolio volatility.